Laboratory Corporation of America Holdings (NYSE:LH) Q1 2024 Earnings Call Transcript
Laboratory Corporation of America Holdings beats earnings expectations. Reported EPS is $3.68, expectations were $3.46.
Source: insidermonkey.com
📰 Plasma Detect News
Plasma Detect News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Plasma Detect. Real-time updates on events, politics, business and more.
Labcorp Announces 2024 First Quarter Results
Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year:Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7%Diluted EPS:...
United States Adam Schechter Early Development Research Laboratories Commercialization Services Clinical Development Bioreference Health
Source: marketscreener.com
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement underscores Labcorp's dedication to ...
San Diego United States Brian Caveney Kimbrel Arculeo Christin Odonnell Development Of Antibody Drug Conjugates
Source: pharmiweb.com
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs
BURLINGTON - Labcorp , a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to...
United States San Diego Kimbrel Arculeo Christin Odonnell Brian Caveney Development Of Antibody Drug Conjugates
Source: marketscreener.com
Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular residual disease (MRD) solution in early stage colon cancer ...
United States Christin Odonnell Kimbrel Arculeo Remond Fijneman Shakti Ramkissoon Netherlands Cancer Institute
Source: pharmiweb.com
Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research
/PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp® Plasma Detect™,...
United States Remond Fijneman Shakti Ramkissoon American Association For Cancer Research Netherlands Cancer Institute Genome Diagnostics Inc
Source: prnewswire.com